Loading clinical trials...
Loading clinical trials...
An Open Label, On-Treatment Trial to Assess the Effect of HIV-1 Coinfection on Therapeutic Responses Using Boceprevir, Peg-Interferon-alfa-2b and Ribavirin in HCV Genotype 1, IFN Treatment-Naive Subjects With or Without HIV-1
Conditions
Interventions
Boceprevir
Peg-Interferon-alfa 2B
+1 more
Locations
2
United States
Unity Health Care, Inc./DC General
Washington D.C., District of Columbia, United States
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Start Date
September 1, 2011
Primary Completion Date
September 1, 2013
Completion Date
September 1, 2013
Last Updated
July 13, 2015
NCT06632444
NCT07024641
NCT02815891
NCT07442760
NCT06741631
NCT06953479
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions